M Pharmaceutical Inc (MPHMF) Stock Rating Upgraded by Zacks Investment Research

m-pharmaceutical-inc-mphmf-stock-rating-upgraded-by-zacks-investment-research.png

M Pharmaceutical Inc (NASDAQ:MPHMF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday.
According to Zacks, “M Pharmaceutical Inc. develops and commercializes biomedical technologies for treatment of obesity, diabetes and other gastroenterological indications primarily in Canada. The Company’s technology consists of Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity; Trimtec, gastrointestinal neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach and eMosquito wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics. M Pharmaceutical Inc. is headquartered in Vancouver, Canada. “
M Pharmaceutical (NASDAQ:MPHMF) traded up 0.000% during midday trading on Tuesday, hitting $0.102. The company’s 50 day moving average price is $0.00 and its 200 day moving average price is $0.00. M Pharmaceutical has a 1-year low of $0.01 and a 1-year high of $0.12. The firm’s market cap is $9.12 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/17/m-pharmaceutical-inc-mphmf-stock-rating-upgraded-by-zacks-investment-research.html

About M Pharmaceutical
M Pharmaceutical Inc, formerly First Sahara Energy Inc, is a biomedical technology company. The Company is engaged in developing and commercializing drug treatments and biomedical technologies for the treatment of obesity and weight loss. The Company’s biomedical technologies include Trimeo, Trimtec and eMosquito.

Get a free copy of the Zacks research report on M Pharmaceutical (MPHMF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for M Pharmaceutical Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for M Pharmaceutical Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "M Pharmaceutical Inc (MPHMF) Stock Rating Upgraded by Zacks Investment Research"

Leave a comment

Your email address will not be published.


*